Journal: iScience

Article Title: TIAR and FMRP shape pro-survival nascent proteome of leukemia cells in the bone marrow microenvironment

doi: 10.1016/j.isci.2023.106543

Figure Lengend Snippet:

Article Snippet: Antibodies used to develop the Western blots were: anti-ATF4 (Proteintech, #10835-I-AP), anti-α-tubulin (Calbiochem, #CP06-100UG), anti-β-actin (Sigma Aldrich, #A5316), anti-eIF2α (CellSignaling, #2103), anti-phospho Ser51-eIF2α (Cell Signaling, #9721), anti-eIF4E (Cell Signaling, #2067), anti-phospho Ser209-eIF4E (Cell Signaling, #9741), anti-FMRP (Bethyl, #A305-199A), anti-FXR1P (Santa Cruz Biotechnology, #sc-374148), anti-FXR2P (Santa Cruz Biotechnology, #sc-376963), anti-GAPDH (Bethyl, #A300-639A), anti-G3BP1 (Proteintech, #66486-1-Ig), anti-HIF1α (Cell Signaling, #14179), anti-HIF2α (Bethyl, #A700-003-T), anti-HuR (Santa Cruz Biotechnology, #sc-5261), anti-PABP (Proteintech, #10970-1-AP), anti-PARP1 (CellSignaling, #9532), anti-PPP5C (Proteintech, #11715-1-AP), anti-phospho Ser371-p70S6K (CellSignaling, #9208), anti-RPL6 (Proteintech, #15387-1-AP), anti-RPL10 (Cell Signaling, #72912), anti-RPL17 (Proteintech, #67223-1-Ig), anti-RPL18 (Proteintech, #17029-1-AP), anti-RPL21 (Proteintech, #15226-1-AP), anti-RPL28 (Proteintech, #16649-1-AP), anti-RPL31 (Proteintech, #16497-1-AP), anti-RPL37A (Proteintech, #14660-1-AP), anti-RPS2 (Abcam, #ab264336), anti-RPS3 (Proteintech, #66046-1-Ig), anti-RPS6 (Proteintech, #66886-1-Ig), anti-RPS15 (Proteintech, #14957-1-AP), anti-Tia-1 (Proteintech, #12133-2-AP), anti-TIAR (Bethyl, #A303-613A), anti-mTOR (CellSignaling, #2983), anti-phospho Ser2448–mTOR (CellSingaling, #5536), anti-Smad3 (Proteitech, #66516-1-Ig), anti-phospho Ser423/425-Smad3 (CellSignaling, #9520), anti-ZW10 (Proteintech, #24561-1-AP), and secondary antibodies: conjugated with horseradish peroxidase (HRP) goat anti-mouse (Dako, #P0447) and goat anti-rabbit (Dako, #P0448) or StarBright Blue 700 conjugated goat anti-rabbit IgG (Bio-Rad, #12004162) and StarBright Blue 520 conjugated goat anti-mouse IgG (Bio-Rad, #12005867).

Techniques: Purification, Virus, shRNA, Control, Transduction, Knockdown, Recombinant, Extraction, Reporter Assay, Lysis, Plasmid Preparation, Software

Journal: Nutrients

Article Title: l -Leucine Supplementation Worsens the Adiposity of Already Obese Rats by Promoting a Hypothalamic Pattern of Gene Expression that Favors Fat Accumulation

doi: 10.3390/nu6041364

Figure Lengend Snippet: Primer sequences.

Article Snippet: RPL-37A , RN02114291_s1 , * , * , *.

Techniques:

Journal: Cell reports

Article Title: RIPK1 activation mediates neuroinflammation and disease progression in multiple sclerosis

doi: 10.1016/j.celrep.2021.109112

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: RPL37A-VIC: Hs01102345 (TaqMan Gene Expression Assays) , ThermoFisher , N/A.

Techniques: Labeling, Recombinant, Sequencing, Selection, Reverse Transcription, Enzyme-linked Immunosorbent Assay, Adjuvant, RNAscope, Gene Expression, Software

Journal: The Journal of Cell Biology

Article Title: Nucleolar protein B23/nucleophosmin regulates the vertebrate SUMO pathway through SENP3 and SENP5 proteases

doi: 10.1083/jcb.200807185

Figure Lengend Snippet: Enhanced SUMO modification of RPL37A and GNL2 after depletion of SENP3 and SENP5. U2OS stably expressing full-length His-tagged versions of SUMO-1 and SUMO-2 (His-SUMO1F and His-SUMO2F) were transfected with siRNAs for codepletion of SENP3 and SENP5 or with control oligonucleotides. After 72 h, the cells were harvested and His 6 -SUMO–modified proteins were isolated. Total cell extracts and His 6 affinity fractions were analyzed by Western blotting with antibodies against RPL37A (top), GNL2 (middle), or B23/nucleophosmin (bottom).

Article Snippet: Rabbit anti-RPL37A and anti-GNL2 antibodies were obtained from Abnova.

Techniques: Modification, Stable Transfection, Expressing, Transfection, Control, Isolation, Western Blot